# REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 Annual Balance Sheet

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: As of 2024-12-31
- Filing: FY2024 10-K, filed 2025-02-05, accession number 0001804220-25-000011
- Page: https://plicit.ai/financials/regn/fy2024-annual-balance-sheet
- Chart image: https://plicit.ai/charts/regn-fy2024-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 37,759,400,000 US dollars
- **Current assets**: 18,660,900,000 US dollars
- **Non-current assets**: 19,098,500,000 US dollars
- **Liabilities**: 8,405,800,000 US dollars
- **Current liabilities**: 3,944,300,000 US dollars
- **Non-current liabilities**: 4,461,500,000 US dollars
- **Equity**: 29,353,600,000 US dollars
- **Marketable securities**: 6,524,300,000 US dollars
- **Accounts receivable, net**: 6,211,900,000 US dollars
- **Inventories**: 3,087,300,000 US dollars
- **Cash and cash equivalents**: 2,488,200,000 US dollars
- **Prepaid expenses and other current assets**: 349,200,000 US dollars
- **Marketable securities**: 8,900,100,000 US dollars
- **Property, plant, and equipment, net**: 4,599,700,000 US dollars
- **Deferred tax assets**: 3,314,100,000 US dollars
- **Intangible assets, net**: 1,148,600,000 US dollars
- **Other noncurrent assets**: 1,136,000,000 US dollars
- **Accrued expenses and other current liabilities**: 2,527,100,000 US dollars
- **Accounts payable**: 789,500,000 US dollars
- **Deferred revenue**: 627,700,000 US dollars
- **Long-term debt**: 1,984,400,000 US dollars
- **Other noncurrent liabilities**: 1,571,400,000 US dollars
- **Finance lease liabilities**: 720,000,000 US dollars
- **Deferred revenue**: 185,700,000 US dollars
- **Retained earnings**: 31,672,900,000 US dollars
- **Additional paid-in capital**: 12,855,900,000 US dollars
- **Common stock - Common Stock**: 100,000 US dollars
- **Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none**: 0 US dollars
- **Common stock - Class A Stock**: 0 US dollars
- **Treasury Stock, at cost; 28.2 shares in 2024 and 25.5 shares in 2023**: negative 15,167,400,000 US dollars
- **Accumulated other comprehensive loss**: negative 7,900,000 US dollars
- **Gross equity (calculated)**: 44,528,900,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.